

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 74768

Title: How to improve metastatic pancreatic ductal adenocarcinoma patients' selection:

between clinical trials and real-world

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03808001 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Sweden

Author's Country/Territory: Italy

Manuscript submission date: 2022-01-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-12 08:06

Reviewer performed review: 2022-01-12 08:22

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Pretta A et al provided a description of a real-world series on PDAC patients treated in a second-line setting for PDAC. The letter underlines an important issue, which is the need of finding personalized treatments, especially after the first cycle of chemotherapy. Considering the small number of patients I think that a realistic analysis through the Kaplan Maier might suffer from an unavoidable lack of statistical power, especially in the presence of few or single events. I suggest including a comment on the small number of patients as a limitation to draw solid results. The letter is well written and is suitable for publication.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 74768

Title: How to improve metastatic pancreatic ductal adenocarcinoma patients' selection:

between clinical trials and real-world

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05231286 Position: Editorial Board Academic degree: MD, PhD

Professional title: Associate Chief Physician

Reviewer's Country/Territory: China

Author's Country/Territory: Italy

Manuscript submission date: 2022-01-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-20 12:29

Reviewer performed review: 2022-01-27 02:37

Review time: 6 Days and 14 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer statements

Peer-Review: [Y] Anonymous [] Onymous

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Thanks for the authors work. 1. the title, abstract, keywords, background, and methods were described properly. 2. It is recommended to use frequency (percentage) for statistical representation of a report with small sample in Table 1. 3. Brief figure legends should be added in Figures. 4. Ethics statement is required.